Difference between revisions of "Belinostat (Beleodaq)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (14 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Histone deacetylase (HDAC) inhibitor. | + | Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.<ref name=insert>[https://beleodaq.com/wp-content/uploads/2019/11/PI-BELEODAQ-200120.pdf Belinostat (Beleodaq) package insert]</ref><ref>[[:File:Belinostat.pdf | Belinostat (Beleodaq) package insert (locally hosted backup)]]</ref><ref>[http://beleodaq.com/ Beleodaq manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is established ''(work in progress)''== | ||
| + | *[[Peripheral T-cell lymphoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Cutaneous T-cell lymphoma]] | *[[Cutaneous T-cell lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | * | + | *[https://beleodaq.com/wp-content/uploads/2019/11/PI-BELEODAQ-200120.pdf Belinostat (Beleodaq) package insert]<ref name=insert></ref> |
| − | *[ | + | *[https://chemocare.com/druginfo/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/belinostat.aspx Belinostat (Beleodaq) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/belinostat-patient-drug-information Belinostat (Beleodaq) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2014-07-03: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm FDA accelerated approval] for the treatment of patients with relapsed or refractory [[Peripheral_T-cell_lymphoma | peripheral T-cell lymphoma (PTCL)]]. ''(Based on BELIEF)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' PXD-101 |
*'''Brand name:''' Beleodaq | *'''Brand name:''' Beleodaq | ||
Latest revision as of 00:58, 29 June 2024
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Belinostat (Beleodaq) package insert[1]
- Belinostat (Beleodaq) patient drug information (Chemocare)[4]
- Belinostat (Beleodaq) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2014-07-03: FDA accelerated approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (Based on BELIEF)
Also known as
- Code name: PXD-101
- Brand name: Beleodaq